Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00455754
Status:
UNKNOWN
Last Update Posted:
2007-04-04
First Post:
2007-04-03
Brief Title:
Esomeprazole Treatment for Patients With Lymphocytic Gastritis
Sponsor:
Technische Universität Dresden
Organization:
Technische Universität Dresden
Study Overview
Official Title:
Double-Blind Randomized Placebo-Controlled Multicenter Trial on the Efficacy of Esomeprazole Treatment for Patients With Lymphocytic Gastritis
Status:
UNKNOWN
Status Verified Date:
2007-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LYNEX
Brief Summary:
The purpose of this study is to determine whether treatment with esomeprazole alone is able to heal patients with lymphocytic gastritis
Detailed Description:
Recently a placebo controlled trial of our group has shown that H pylori eradication therapy consisting of omeprazole 20 mg bid clarithromycin 500 mg bid amoxicillin 1000 mg bid for seven days leads to a complete long-lasting resolution of lymphocytic gastritis in 96 of patients However after 3 months we also found a healing rate of 50 in patients who received omeprazole 20 mg bid and placebo antibiotics for seven days suggesting spontaneous remission or a potential PPI effect Thus we speculate that PPI therapy may have led to elimination of H pylori and subsequently healing of lymphocytic gastritis in those patients with potentially minimal H pylori colonization at baseline For this reason we investigate whether a PPI treatment alone is able to heal patients with lymphocytic gastritis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None